Tags

Type your tag names separated by a space and hit enter

Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
Liver Transpl. 2011 Mar; 17(3):331-3.LT

Abstract

Statins are relatively safe first-line agents to use in the setting of dyslipidemia associated with immunosuppressive therapy in subjects undergoing liver transplantation, and also in HIV-infected patients with dyslipidemia due to antiretroviral drugs, especially ritonavir-boosted protease inhibitors. Rosuvastatin, a new statin, has demonstrated higher potency than previously released statins and is not extensively metabolized by the liver P450 system; therefore, the probability of deleterious pharmacokinetic interactions with commonly used immunosuppressants and antiretroviral drugs is reduced. We present the first case of severe rhabdomyolysis in a liver transplant patient receiving rosuvastatin for the treatment of immunosuppressive therapy-related grade IV dyslipidemia, an HIV-infected subject on protease inhibitor-sparing HAART, that resolved after rosuvastatin withdrawal, probably related to interactions between calcineurin inhibitors and hepatic rosuvastatin uptake transporters such as organic anion transporting polypeptides (OATPs).

Authors+Show Affiliations

Infectious Diseases Service, Hospital Ramón y Cajal, Madrid, Spain. amoreno.hrc@salud.madrid.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

21384516

Citation

Moreno, Ana, et al. "Severe Rhabdomyolysis Due to Rosuvastatin in a Liver Transplant Subject With Human Immunodeficiency Virus and Immunosuppressive Therapy-related Dyslipidemia." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol. 17, no. 3, 2011, pp. 331-3.
Moreno A, Fortún J, Graus J, et al. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transpl. 2011;17(3):331-3.
Moreno, A., Fortún, J., Graus, J., Rodriguez-Gandía, M. A., Quereda, C., Pérez-Elías, M. J., Nuño, J., Wikman, P., Moreno, S., & Bárcena, R. (2011). Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 17(3), 331-3. https://doi.org/10.1002/lt.22225
Moreno A, et al. Severe Rhabdomyolysis Due to Rosuvastatin in a Liver Transplant Subject With Human Immunodeficiency Virus and Immunosuppressive Therapy-related Dyslipidemia. Liver Transpl. 2011;17(3):331-3. PubMed PMID: 21384516.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. AU - Moreno,Ana, AU - Fortún,Jesús, AU - Graus,Javier, AU - Rodriguez-Gandía,Miguel A, AU - Quereda,Carmen, AU - Pérez-Elías,María J, AU - Nuño,Javier, AU - Wikman,Philip, AU - Moreno,Santiago, AU - Bárcena,Rafael, PY - 2011/3/9/entrez PY - 2011/3/9/pubmed PY - 2011/6/28/medline SP - 331 EP - 3 JF - Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society JO - Liver Transpl. VL - 17 IS - 3 N2 - Statins are relatively safe first-line agents to use in the setting of dyslipidemia associated with immunosuppressive therapy in subjects undergoing liver transplantation, and also in HIV-infected patients with dyslipidemia due to antiretroviral drugs, especially ritonavir-boosted protease inhibitors. Rosuvastatin, a new statin, has demonstrated higher potency than previously released statins and is not extensively metabolized by the liver P450 system; therefore, the probability of deleterious pharmacokinetic interactions with commonly used immunosuppressants and antiretroviral drugs is reduced. We present the first case of severe rhabdomyolysis in a liver transplant patient receiving rosuvastatin for the treatment of immunosuppressive therapy-related grade IV dyslipidemia, an HIV-infected subject on protease inhibitor-sparing HAART, that resolved after rosuvastatin withdrawal, probably related to interactions between calcineurin inhibitors and hepatic rosuvastatin uptake transporters such as organic anion transporting polypeptides (OATPs). SN - 1527-6473 UR - https://www.unboundmedicine.com/medline/citation/21384516/Severe_rhabdomyolysis_due_to_rosuvastatin_in_a_liver_transplant_subject_with_human_immunodeficiency_virus_and_immunosuppressive_therapy_related_dyslipidemia_ L2 - https://doi.org/10.1002/lt.22225 DB - PRIME DP - Unbound Medicine ER -